Figure S1 from Combination of the MTA-Cooperative PRMT5 Inhibitor BMS-986504 and KRAS Inhibitors Is an Effective Treatment Strategy for MTAP-Deleted KRAS-Mutant Pancreatic Cancer
Combination therapy significantly improves treatment efficacy in pancreatic cancer.
MTAP-deletion status influences the effectiveness of PRMT5 inhibitors in cancer treatment.
Cell cycle analysis reveals critical insights into the effects of PRMT5 inhibition.
The study highlights a potential strategy for targeting KRAS-mutant cancers.
simple_explanation: MTAP-deleted pancreatic cancer cells respond better to a mix of PRMT5 and KRAS inhibitors. The treatment shows promising results in slowing down cell growth and affecting the cell cycle. This approach could change how we treat certain aggressive pancreatic cancers, offering hope for improved patient outcomes.
Abstract
Figure S1 shows MTAP-deletion status of PDAC cell lines and cell cycle analysis of PRMT5i-treated cells.
Ask AI
Helpful
Bookmark
Share
View Full Paper
Cite This Study
Drizyte‐Miller et al. (2025) studied this question.